Objective: To present the results of the nonrandomized arm of the Cervical Artery Dissection in Stroke Study (CADISS-NR) trial, comparing anticoagulation and antiplatelets for prevention of recurrent stroke after carotid and vertebral dissection, and perform a meta-analysis of these results with previously published studies comparing the 2 therapeutic strategies.
Conclusion:
There is no evidence for superiority of anticoagulation or antiplatelet therapy in prevention of stoke after carotid and vertebral artery dissection; however, all data are from nonrandomized studies and randomized studies are required. The nonrandomized CADISS data show a lower rate of recurrent stroke than reported in some previous studies.
Clinical Trial Registration Information: www.dissection.co.uk, ISRNCTN44555237. Neurology Cervical artery dissection (CAD) accounts for 1%-2% of ischemic strokes, but is important in the young, in whom it may account for 10%-25%. 1 Embolism from thrombus at the dissection site is thought to be important in stroke pathogenesis.
Prospective studies suggest a high early risk of recurrent stroke in CAD 2-4 but this finding is not consistent. 1, 5 This has led to the use of antithrombotic therapy in stroke prevention. Whether anticoagulants or antiplatelets are more effective is unknown; physicians have widely differing practice. 6 No randomized trials have examined this question. Previous meta-analyses have shown no difference between the 2 treatments 7,8 but studies have been small and subject to selection bias.
The Cervical Artery Dissection in Stroke Study (CADISS) trial (ISRNCTN44555237, www.dissection.co.uk) is addressing this question. It is currently in a feasibility phase with a sample size of 250. 9 It included a nonrandomized arm (CADISS-NR), to obtain information on patients unsuitable for randomization, which has now completed. We present these results, and include them in meta-analysis with previously published data.
METHODS CADISS-NR. CADISS is a multicenter prospective study comparing antiplatelets with anticoagulation in CAD. Patients are randomized within 7 days of symptom onset. Inclusion criteria for both randomized and nonrandomized arms are radiologic evidence of extracranial carotid or vertebral dissection presenting with ipsilateral TIA or stroke (including retinal ischemia) or ipsilateral Horner syndrome, or headache or neck pain, with known date of onset. Evidence of dissection must be on MRI/magnetic resonance angiography or CT angiography or intra-arterial angiography, with images reviewed by coordinating center neuroradiologists.
Additional exclusion criteria for the randomized arm include symptom onset Ͼ7 days and contraindications to, or already taking for other reasons, antiplatelets/anticoagulants. Patients with history of trauma, except penetrating trauma, were included. Patients not eligible for recruitment into the randomized arm were eligible for inclusion into CADISS-NR for which subjects needed to be within 31 days of symptom onset.
Patients were treated with antiplatelets or anticoagulation at the discretion of the attending physician. Low-dose heparin for thrombosis prophylaxis was allowed.
At baseline, clinical assessment, information on vascular risk factors, history of trauma, and medications were recorded. Patients were reviewed in person at 3 months. Telephone follow-up by coordinating center doctors was performed at 6 and 12 months.
Primary endpoint was stroke, or death from any cause, within 3 months of recruitment. Secondary endpoints included ipsilateral TIA; ipsilateral stroke or TIA; any stroke; any stroke or death (from any cause). All endpoints were centrally adjudicated with review of clinical and imaging details. TIA was defined clinically.
The local ethics committee approved the study(04/Q0803/ 215) and patients gave written consent. Search terms were (carotid artery or vertebral artery or cervical artery or anterior circulation or posterior circulation or extracranial carotid artery) and (dissection) and (antiplatelet or anticoagulant). The search terms carotid artery dissection treatment and vertebral artery dissection treatment were also used.
Meta-analysis.
Studies were included if they contained outcome data allowing comparison of patients on antiplatelets or anticoagulants. Exclusion criteria were Ͻ4 patients; primary intracranial dissection; unclear specification of treatment groups. Endpoints evaluated were ipsilateral stroke, any cause death, TIA, and stroke. Patients who received both antiplatelets and anticoagulants were excluded.
Statistical analysis. Meta-analysis was performed using Review Manager V(http://ims.cochrane.org/revman). A risk difference with fixed effects model was used; a positive difference favors anticoagulation. Odds ratios (OR) were also calculated looking at the overall events as a secondary outcome.
RESULTS CADISS-NR. Eighty-eight patients were recruited from 22 centers (table). Data on 7 additional patients who presented Ͼ1 month after symptom onset were not included, as these did not meet inclusion criteria. Over the same period, 75 patients entered the randomized arm. Mean time from symptom onset was 10.8 (SD 7.0, range 1-31) days.
Reasons for exclusion from randomized arm were presented Ͼ7 days (53), contraindication to antiplatelets/anticoagulants (12), already on antiplatelets/anticoagulation for other reasons (5), patient or physician unwilling to randomize (18).
Follow-up of the primary endpoint at 3 months was obtained in 87 (98.8%). Fifty-nine patients were treated with antiplatelets: aspirin alone 30, aspirin and clopidogrel 14, aspirin and dipyridamole 12, clopidogrel alone 3. Twentyeight were treated with anticoagulation: 23 low molecular heparin and warfarin, 5 warfarin alone: 6 on antiplatelets and 2 on anticoagulation had been treated with IV thrombolysis.
One patient on antiplatelets (1.69%) and 1 on anticoagulation (3.57%) had recurrent stroke within 3 months, both in the same territory as the initial dissection (left carotid artery). A total of 3 (5.08%) patients on antiplatelets had recurrent TIA, compared with none on anticoagulants; 2 in the same territory as the initial dissection, and 1 in contralateral carotid. All patients with TIA had brain CT or MRI but no new infarcts were identified.
There were no deaths or serious adverse events in either group. One patient on heparin and warfarin had hematuria which resolved spontaneously; anticoagulation was continued. Of 8 patients treated with IV thrombolysis, none had recurrent events in the following 24 hours or other complications.
The primary endpoint was 3 months; however, follow-up was continued in 87 patients at 6 and 12 months. There was 1 additional endpoint; the patient who had TIA and stroke in the left carotid ter- Figure 1 Forest plot comparing stroke rates in patients treated with antiplatelet therapy vs anticoagulants (fixed effects model)
Studies are denoted by reference number (for e-references, see supplemental data). CADISS ϭ Cervical Artery Dissection in Stroke Study; CI ϭ confidence interval.
ritory at 3 months had further MRI-confirmed stroke in the same territory at 6 months, on antiplatelets, and died a few months later from pulmonary embolism and sepsis.
Systematic review and meta-analysis. The search resulted in 3,249 citations, from which 212 potentially relevant abstracts were identified. Of these, 39 met inclusion criteria 3,e2-e38 : 23 related to carotid dissection, 3 to vertebral, and 13 to both. Three-month follow-up results in CADISS-NR were included.
There were 33 recurrent strokes, 13/499 (2.6%) on antiplatelets and 20/1,137 (1.8%) on anticoagulants (OR 1.49). The risk difference was not significant (0.00 [Ϫ0.02, 0.03], p ϭ 0.79) (forest plot, figure 1 ).
For analysis of combined endpoint of TIA and stroke, 1 study which did not record recurrent TIA was excluded.
e35 A total of 31 of 416 (7.5%) on antiplatelets and 41/1,090 (3.8%) on anticoagulants had TIA or stroke (OR 2.06). This result showed a significant difference (0.04 [0.01, 0.08], p ϭ 0.02; forest plot figure e-1 on the Neurology ® Web site at www.neurology.org), but there was heterogeneity; therefore a random effects model was performed which showed no difference between treatments (0.03 [Ϫ0.02, 0.08], p ϭ 0.29; forest plot figure e-2).
There were 14 deaths, 5/499 (1.0%) on antiplatelets and 9/1,137 (0.8%) on anticoagulants (OR 1.27). The risk difference was not significant (Ϫ0.00 [Ϫ0.03, 0.02], p ϭ 0.89; forest plot figure e-3).
DISCUSSION
In this prospective study, we found no difference between antiplatelets and anticoagulants in prevention of recurrent stroke in CAD. We combined these data with a systematic review including over 1,600 patients. This also found no difference.
In CADISS-NR, there was a low recurrent stroke rate of 2.3%. Some prospective studies have suggested a higher rate, particularly early after presentation. 8 -10 Median time to recruitment in CADISS-NR was 10.8 days; with earlier recruitment the risk may be higher. However, other studies have suggested a lower recurrent stroke rate. e32,e36,e39
We found no difference in death rates between the treatments in either CADISS-NR or the metaanalysis. It has been suggested anticoagulants could result in extension of the intramural hematoma but our data do not support this.
CADISS-NR, and this updated meta-analysis, provides data on a large sample to address the effectiveness of treatment options in CAD. However, these data have limitations. All are from nonrandomized studies, and most were not designed to examine this question. Different treatment regimens were used for both anticoagulation and antiplatelet therapy. More robust data will be obtained from randomized trials such as CADISS.
